中国临床药理学与治疗学2025，Vol.30Issue(4)：433-445,13.DOI:10.12092/j.issn.1009-2501.2025.04.001
模型引导的抗排异治疗患者他克莫司精准用药专家共识
Expert consensus on the model informed precision dosing of tacroli-mus in patients receiving anti-rejection therapy
摘要
Abstract
There is significant inter-individual variation of pharmacokinetics and pharmacody-namics in patients receiving tacrolimus(TAC)for an-ti-rejection therapy,which cause the rejection or toxic action.Based on results of therapeutic drug monitoring and pathophysiological index of trans-plant patients,the individualized dosing regimen can be designed and adjusted by using model in-formed precision dosing(MIPD).The patients'clini-cal outcome can be improved.In the consensus,the different methods of MIPD used for patients re-ceived TAC for anti-rejection therapy were intro-duced,which can be used for the designing and ad-justing doing regimen,predicting adverse drug reac-tion,improving medication adherence and econom-ics during therapy.关键词
他克莫司/模型引导的精准用药/治疗药物监测/专家共识Key words
tacrolimus/model informed preci-sion dosing(MIPD)/therapeutic drug monitoring(TDM)/consensus分类
药学引用本文复制引用
陈冰,李晓宇,张弋,赵维,王玉珠,高建军,焦正,左笑丛,李新刚,尚德为,周佩军,丁俊杰,相小强,邱晓燕,王卓..模型引导的抗排异治疗患者他克莫司精准用药专家共识[J].中国临床药理学与治疗学,2025,30(4):433-445,13.基金项目
国家自然科学基金(81973387,82073933) （81973387,82073933）
